IntegriChain Will Speak at Three Industry Conferences
Philadelphia-based IntegriChain leaders will discuss drug pricing and policy during sessions scheduled for late 2026.
Updated on Sept. 29, 2026 in Healthcare
Beginning October 5, 2026, representatives from the Philadelphia-based firm IntegriChain will share expertise across three major pharmaceutical conferences. These sessions address critical topics such as government pricing, 340B claims, and industry distribution strategy.
Why it matters
Pharmaceutical manufacturers are navigating complex regulatory and reimbursement pressures that significantly impact their market access and overall revenue. Expert participation at these summits provides industry stakeholders with actionable insights to manage these financial variables.
IntegriChain executives will appear at three industry conferences through December 2026. The firm engages with the Revenue Analytics Collaborative, which includes more than 800 members focused on industry trends.
The players
IntegriChain
This Philadelphia-based company provides commercial technology and data solutions to life sciences organizations.
Jeff Baab
He is an IntegriChain representative scheduled to present on government drug pricing.
Clay Willis
He is an IntegriChain representative who will speak on 340B claims.
Jennifer Sharpe
She is an IntegriChain representative who will moderate a roundtable at the November summit.
Bill Roth
He is an IntegriChain representative slated to deliver a keynote address in December.
The details
IntegriChain officials will lead presentations and keynotes on government drug pricing, 340B claims, and distribution policy. These contributions aim to support manufacturers facing tightening reimbursement requirements.
Timeline
The Medicaid Drug Rebate Program Summit is set for Oct. 5-7, 2026.
IntegriChain presentations in Chicago are scheduled for Oct. 7, 2026.
The Pharma/Biotech Gross-to-Net Summit takes place Nov. 16-18, 2026.
The Trade & Channel Strategies conference runs Dec. 8-10, 2026.
Market Landscape
The participation of specialized firms in these summits reflects the growing necessity for data-driven precision in the face of complex regulatory environments. This positions IntegriChain as a key advisor for companies seeking to maintain market access under the Medicaid Drug Rebate Program.
For pharmaceutical stakeholders and industry partners, these conferences represent critical windows into shifting government pricing and reimbursement policies. The insights shared by these experts can influence how manufacturers manage distribution and patient access programs.
The takeaway
Understanding the intricacies of government pricing and 340B claims is essential for navigating the modern pharmaceutical landscape. Stakeholders should leverage these industry insights to better align their commercial strategies with current regulatory expectations.
Further reading
Learn more about the latest developments in Healthcare.
Source note: This article includes information reported by MyChesCo.
